Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by KalVista Pharmaceuticals, Inc. < Previous 1 2 3 4 Next > KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting February 16, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants February 15, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants February 14, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema February 13, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology December 20, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update December 07, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 05, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology November 14, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved November 13, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present at Upcoming Investor Conferences November 07, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 03, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology November 02, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference October 24, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 03, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference September 19, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update September 07, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA August 28, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 02, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer July 25, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit July 24, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results July 07, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 05, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology June 12, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 05, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) June 02, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference May 31, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference May 23, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop May 08, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 02, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire Tickers KALV < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.